New therapy for vasculitis will help patients avoid infertility and cancer

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. The news will be presented October 18 at the annual meeting of the American College of Rheumatology in Philadelphia.

Read the whole article on Physorg

More from Physorg